DeepMed Research

Saxagliptin

Generic Name: Saxagliptin

Brand Names: Kombiglyze, Komboglyze, Onglyza, Qtern, Qternmet

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₅N_₃O_₂

CAS Number: 361442-04-8

Unique Ingredient Identifier: 8I7IO46IVQ

Background: Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

Indication: Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.

Associated Conditions: Type 2 Diabetes Mellitus

Clinical Trials

Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control

Phase 3

Completed

Conditions: Type2diabetes

Interventions: Drug: Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg
Drug: Insulin Glargine 100 UNT/ML Pen Injector [Lantus]
Drug: Pioglitazone 30mg

First Posted Date: 2023-10-30

Last Posted Date: 2025-03-30

Lead Sponsor: University of Basrah

Target Recruit Count: 243

Registration Number: NCT06107153

Locations: 🇮🇶
Faiha Specialized Diabetes, Endocrine, and Metabolism Center, Basrah, Iraq

Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: DPP4 inhibitor
Drug: 2nd generation Sulfonylurea
Drug: Liraglutide
Drug: Canagliflozin
Drug: Saxagliptin

First Posted Date: 2023-10-25

Last Posted Date: 2023-10-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 239990

Registration Number: NCT06099067

Locations: 🇸🇪
Research Site, Gothenburg, Sweden

Cognitive Protective Effect of Newer Antidiabetic Drugs

Conditions: Type 2 Diabetes

Interventions: Drug: Dapagliflozin
Drug: Empagliflozin
Drug: Canagliflozin
Drug: Sitagliptin
Drug: Saxagliptin
Drug: Linagliptin
Drug: Vildagliptin

First Posted Date: 2022-04-26

Last Posted Date: 2022-07-26

Lead Sponsor: Alexandria University

Target Recruit Count: 100

Registration Number: NCT05347459

Locations: 🇪🇬
Alexandria University, Alexandria, Egypt

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Recruiting

Conditions: Type 2 Diabetes Mellitus
Cardiovascular Diseases

First Posted Date: 2021-10-11

Last Posted Date: 2024-10-24

Lead Sponsor: Kaiser Permanente

Target Recruit Count: 270000

Registration Number: NCT05073692

Locations: 🇺🇸
Romain S. Neugebauer, Oakland, California, United States
🇺🇸
Kaiser Permanente Southern California, Pasadena, California, United States
🇺🇸
Kaiser Permanente Hawaii, Honolulu, Hawaii, United States

and more 3 locations

Tubular Markers in Response to Saxagliptin Therapy

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Saxagliptin 5mg

First Posted Date: 2020-08-20

Last Posted Date: 2020-08-20

Lead Sponsor: Beni-Suef University

Target Recruit Count: 80

Registration Number: NCT04521049

Locations: 🇪🇬
Faculty of Pharmacy, Al Qāhirah Al Jadīdah, Egypt

Evaluation of Drug Interactions of Saxagliptin With Sildenafil in Healthy Volunteers

Not Applicable

Conditions: Diabetes Mellitus, Type 2
Erectile Dysfunction With Diabetes Mellitus
Drug Interaction

Interventions: Drug: Saxagliptin 5mg
Drug: Sildenafil 50 mg

First Posted Date: 2019-11-20

Last Posted Date: 2019-11-20

Lead Sponsor: Ain Shams University

Target Recruit Count: 18

Registration Number: NCT04170790

Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims

Completed

Conditions: Diabetes

Interventions: Drug: Sulfonylurea
Drug: Saxagliptin

First Posted Date: 2019-05-03

Last Posted Date: 2023-08-01

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 182126

Registration Number: NCT03936023

Locations: 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States

Neuropeptide Y and Sympathovagal Balance

Early Phase 1

Completed

Conditions: Physical Activity
Sympathetic Nervous System
Secretion; Catecholamine

Interventions: Drug: Saxagliptin 5mg
Drug: Placebo oral capsule
Other: ergometric test in healthy volunteers

First Posted Date: 2019-05-01

Last Posted Date: 2019-05-01

Lead Sponsor: Eric Grouzmann

Target Recruit Count: 7

Registration Number: NCT03933787

Locations: 🇨🇭
Service de Néphrologie, Lausanne, Vaud, Switzerland

Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.

Phase 2

Completed

Conditions: Type2 Diabetes Mellitus

Interventions: Drug: Saxagliptin 5mg + Dapagliflozin 10 mg
Drug: Dapagliflozin 10mg
Drug: Saxagliptin 5mg

First Posted Date: 2018-10-22

Last Posted Date: 2022-11-08

Lead Sponsor: University of Pisa

Target Recruit Count: 48

Registration Number: NCT03714594

Locations: 🇮🇹
Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy

Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

Phase 4

Terminated

Conditions: Cardiovascular Diseases
Diabetes Mellitus, Type 2

Interventions: Drug: Dapagliflozin 10mg
Drug: Placebo Oral Tablet
Drug: Saxagliptin 5mg

First Posted Date: 2018-09-06

Last Posted Date: 2023-06-05

Lead Sponsor: Sabyasachi Sen

Target Recruit Count: 15

Registration Number: NCT03660683

Locations: 🇺🇸
The GW Medical Faculty Associates, Washington, District of Columbia, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy